Nontuberculous mycobacteria: opportunistic environmental pathogens for predisposed hosts.
Nontuberculous mycobacterial (NTM) infections are caused by environmental mycobacteria. Patients with pulmonary NTM disease usually have predisposing lung abnormalities. Diagnostic methods are evolving. Treatment is largely empiric. Data were extracted from peer reviewed publications, guidelines, and case series. Progressive NTM lung disease should be treated. Multidrug regimens are mostly macrolide based and are occasionally complemented by lung resection. Disease persistence and relapse are not uncommon and are a greater problem with so-called rapid-grower NTM infections. Some of the issues considered in this review are: the role of antibiotic susceptibility testing in predicting treatment effectiveness, optimal drug combinations, daily vs. intermittent dosing intervals for different NTM infections and disease severity, when the goal of cure should be replaced with observation or palliation, and patient selection for surgery. Future needs for development and research include improved epidemiology, definition of genetic and other risk factors, definition of predictors of treatment outcome, multicenter treatment studies, new drug discovery and animal models of disease and treatment.
Cook
James L
JL
Immunology and International Medicine, University of Illinois at Chicago, 808 South Wood Street, Chicago, IL 60612, USA. jlcook@uic.edu
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D008171:Lung Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology
D000900:Anti-Bacterial Agents